Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The information contained in this presentation is accurate only as of the date hereof.

This presentation contains forward-looking statements including statements related to our overall strategy, products, prospects, potential and expected results, including statements about the projected net product revenues including assumptions related to our financial guidance, our anticipated cash runway, our SEYSARA royalty-backed loan funded on May 1, 2019, the progression of our commercial roll out for NUZYRA, our ability to shape the future treatment paradigm for community-acquired pneumonia and serious skin infections, the results of our Phase 2 studies of omadacycline in UTI, our plans to evaluate additional indications for NUZYRA, including NTM, and to work toward an oral-only indication in CABP, and our potential to further drive long-term value for all of our shareholders. All statements, other than statements of historical facts, included in this presentation are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2018 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

PARATEK® and the Hexagon Logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA and its design logo are trademarks of Paratek Pharmaceuticals, Inc. All other trademarks, service marks, trade names, logos and brand names identified in this presentation are the property of their respective owners.
Well-Positioned for Future Growth
Focused on Execution + New Value Creation

NUZYRA® 100mg for injection & 150mg tablets

Near-term Execution

Advance NUZYRA® U.S. Launch
Capitalize on Project BioShield Opportunity
Disciplined Operating Expense Management

Future Value Creation

NUZYRA in Nontuberculous Mycobacteria or “NTM”
Oral-only dosing regimen for NUZYRA in CABP
Product / Pipeline Expansion
## Paratek Investment Highlights

### NUZYRA®: Potential Blockbuster Antibiotic in Both Hospital and Community Settings

| Potential Blockbuster Antibiotic with NUZYRA® | • 1st FDA approved and launched *once-daily oral & IV antibiotic* to treat both CABP and ABSSSI in nearly 20 years*  
| | • > $5 Billion Potential Addressable U.S. Market** |
| Capital Efficient Commercial Model | • *Significant Value Proposition* = Hospitalization Minimization  
| | • *Hospital Promotion* with no other Branded Once-Daily Broad-spectrum Oral + IV Competitors |
| BARDA Project BioShield | • **BARDA Project BioShield contract** awarded to for development of NUZYRA for pulmonary anthrax  
| | • Valued up to $285 million |
| Additional Pipeline Potential | • **Life-cycle opportunities**: Oral-Only CABP, Nontuberculous mycobacteria, Pulmonary Anthrax, Prostatitis, Rickettsial Disease  
| | • Additional **Biodefense opportunities** beyond pulmonary anthrax |
| Strong Balance Sheet | • Cash runway projected through the first half of 2023 |

(*) NUZYRA U.S. FDA-approved in October 2018  
(**) Paratek estimates based on 2015 AMR data current treatment failure rates and a Zyvox 2015 pricing analogue and opportunity reflective of current U.S. label
First-ever Bioshield award for an Antibiotics company

Paratek was the sole recipient

Valued at up to $285 million with potential for extension beyond
- $77 million in reimbursement for all existing post-approval obligations
- $54 million for anthrax development & U.S. onshoring of manufacturing
- $153 million purchase of NUZYRA for the Strategic National Stockpile

Extends cash runway through the first half of 2023
## BARDA Project BioShield Contract Award
*Valued up to $285 million to Paratek*

<table>
<thead>
<tr>
<th>Contract Provisions</th>
<th>Value</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Base Award</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Development of NUZYRA: Treatment of pulmonary anthrax</td>
<td>~$21 million</td>
<td>• Funding period: 2020 through 2024</td>
</tr>
<tr>
<td>• Purchase of an initial 2,500 treatment courses</td>
<td>~$38 million</td>
<td>• 2500 treatment courses: 1H 2020</td>
</tr>
<tr>
<td><strong>Time-Based Options</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• All FDA post marketing requirements including CABP,</td>
<td>~$77 million</td>
<td>• Funding to commence in 2Q 2020 through</td>
</tr>
<tr>
<td>microbiological surveillance and pediatric studies</td>
<td></td>
<td>completion of all studies</td>
</tr>
<tr>
<td>• Manufacturing on-shoring and security-related</td>
<td>~$20 million</td>
<td>• 100% cost reimbursement model</td>
</tr>
<tr>
<td>requirements</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Milestone-based Options</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Three additional purchases of NUZYRA for up to 7,500</td>
<td>~$115 million</td>
<td>• 2500 treatment courses: ~2021</td>
</tr>
<tr>
<td>treatment courses</td>
<td></td>
<td>• 2500 treatment courses: ~2022</td>
</tr>
<tr>
<td>• Development of NUZYRA: Prophylaxis of pulmonary</td>
<td>~$13 million</td>
<td>• 2500 treatment courses: ~2023</td>
</tr>
<tr>
<td>anthrax</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Program to commence with funding: ~2022</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Paratek Pipeline

<table>
<thead>
<tr>
<th>Research</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Registration</th>
<th>Marketed*</th>
<th>Commercial Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NUZYRA®</strong>&lt;br&gt;(omadacycline)&lt;br&gt;100mg for injection &amp; 150mg tablets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Global*)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ABSSSI (IV &amp; Oral) – QIDP + SPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PARATEK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ABSSSI (Oral-only) – QIDP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CABP (IV &amp; Oral) – QIDP + SPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CABP PK Study for Oral-only Labelling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pulmonary Anthrax; Project BioShield</td>
<td></td>
<td></td>
<td>FDA Animal Rule Applies</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SEYSARA®</strong>&lt;br&gt;(sarecycline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(U.S.)</td>
</tr>
<tr>
<td></td>
<td>Inflammatory Acne (Acne Vulgaris)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PARATEK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(ex-U.S.)</td>
</tr>
</tbody>
</table>

+Marketed in the US only
*We have entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ltd., for the greater China region
## Strong Track Record Delivering on Milestones

<table>
<thead>
<tr>
<th>Omadacycline Events</th>
<th>Timing</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSSSI Phase 3 data: IV &amp; oral</td>
<td>Q2 2016</td>
<td>Positive Phase 3 data</td>
</tr>
<tr>
<td>UTI Phase 1b data: PK/PD</td>
<td>Q4 2016</td>
<td>Proof-of-principle</td>
</tr>
<tr>
<td>CABP Phase 3 data: IV &amp; oral</td>
<td>Q2 2017</td>
<td>Positive Phase 3 data</td>
</tr>
<tr>
<td>ABSSSI Phase 3 data: Oral-only</td>
<td>Q3 2017</td>
<td>Positive Phase 3 data</td>
</tr>
<tr>
<td>NDA approval</td>
<td>Oct 2018</td>
<td>Approved</td>
</tr>
<tr>
<td><strong>U.S. Launch</strong></td>
<td><strong>Feb 2019</strong></td>
<td><strong>Launched</strong></td>
</tr>
<tr>
<td>BARDA - Project BioShield Contract</td>
<td>Dec 2019</td>
<td>Awarded</td>
</tr>
<tr>
<td>Receive Emergency Use Authorization designation for NUZYRA in anthrax</td>
<td>Q1 2020</td>
<td></td>
</tr>
<tr>
<td>Execute purchase of initial 2,500 treatment courses for BARDA Project BioShield</td>
<td>Q1-Q2 2020</td>
<td></td>
</tr>
<tr>
<td>Initiate FDA post marketing requirements including CABP and pediatric studies</td>
<td>Q2 2020</td>
<td></td>
</tr>
<tr>
<td>Commence manufacturing security-related requirements</td>
<td>Q2 2020</td>
<td></td>
</tr>
<tr>
<td>Determine path forward for NUZYRA in NTM</td>
<td>H1 2020</td>
<td></td>
</tr>
<tr>
<td>Oral-only Indication in CABP</td>
<td>Q4 2020</td>
<td></td>
</tr>
</tbody>
</table>
NUZYRA® Commercial Opportunity
Potential Blockbuster Antibiotic in Both Hospital and Community Settings
NUZYRA®: Attributes Provide A Modern-Day Solution
Addressing Bacterial Resistance and the Needs of Today’s Healthcare Systems

• Once-daily IV & Oral
• Skin and Pneumonia Approved
• No dosage modifications or monitoring in hepatic or renal impairment
• No QTc prolongation
• Low potential for DDIs
• No cases of *C. diff* reported in completed clinical program

- HCP confidence in treating patients
  - Efficacy
  - Safety
  - Tolerability

- Efficacy from hospital to home
  - Helps minimize hospitalization
### Blockbuster Antibiotics: IV & Oral Formulations, Once-daily, “Big 3” Indications

**NUZYRA®: Well Positioned for Future Success**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Broad Spectrum</th>
<th>Big 3(^{(1)}) Indications</th>
<th>Oral Frequency</th>
<th>2010 Sales(^{(3,4)})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levofloxacin</td>
<td>✔️</td>
<td>3</td>
<td>Once Daily</td>
<td>$3.4B</td>
</tr>
<tr>
<td>Co-Amoxy clav</td>
<td>✔️</td>
<td>3</td>
<td>Twice Daily</td>
<td>$2.8B</td>
</tr>
<tr>
<td>Azithromycin(^{(2)})</td>
<td>✔️</td>
<td>2</td>
<td>Once Daily</td>
<td>$1.8B</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>✔️</td>
<td>3</td>
<td>Twice Daily</td>
<td>$1.4B</td>
</tr>
<tr>
<td>Clarithromycin(^{(2)})</td>
<td>✔️</td>
<td>2</td>
<td>Twice Daily</td>
<td>$1.4B</td>
</tr>
<tr>
<td>NUZYRA</td>
<td>✔️</td>
<td>2</td>
<td>Once Daily</td>
<td>N/A</td>
</tr>
</tbody>
</table>

>65% of Revenue was Generated by the Oral Formulations

---

\(^{(1)}\) Skin, Respiratory, UTI

\(^{(2)}\) Both Azithromycin and Clarithromycin did not have UTI claim

\(^{(3)}\) IMS global sales data in 2010

\(^{(4)}\) Major patents had expired for all products by 2010 except Levofloxacin where 2010 was peak year sales
NUZYRA®: As First-line Therapy
Targeted Patient Profiles

CABP

- Alternative to fluoroquinolone + β-lactam allergic
- Prior C. difficile infection

ABSSSI

- Suspected polymicrobial infection + β-lactam / sulfa allergic
- Renal insufficiency + SSRI
U.S. Hospital Skin & Pneumonia Market by 2028
Potential $3.3 Billion Addressable Opportunity for NUZYRA

ABSSSI Opportunity: 1st line treatment (Tx) failure, resistance suspected

3,300K(1) Hospitalized ABSSSI

\[ \sim 12\% (1) \text{ Fail broad sp + MRSA cov} \times \sim 400k \text{ patients} \times \$3,000(3) = \$1.2B \text{ opportunity} \]

CABP Opportunity: 1st line Tx failure, resistance suspected

3,400K(1) Hospitalized CABP

\[ \sim 14\% (2) \text{ Fail FQ or ceph+macrolide} \times \sim 490k \text{ patients} \times \$3,000(3) = \$1.4B \text{ opportunity} \]

---

(1) AMR data (2015): Of patients never receiving confirmed pathogen and getting potential MRSA coverage, 30%+ switch therapies (i.e., to another empiric therapy)
(2) Primary market research (est 18% of hospitalized CABP patients & 16.5% of community CABP patients are “high-risk” and suspected/confirmed to have a resistant pathogen)
(3) Cost per course based on health outcome analysis, 10 day course of therapy and cost of branded Zyvox therapy as an analogue
### U.S. Community Skin and Pneumonia Market by 2028

**Potential $2.6 Billion Addressable Opportunity for NUZYRA**

<table>
<thead>
<tr>
<th>Market</th>
<th>Potential Opportunity</th>
<th>Calculation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABSSSI Opportunity:</strong> Initial treatment (Tx) failure, resistance suspected</td>
<td>~5% of first line MRSA treatment</td>
<td>$1.5B opportunity</td>
</tr>
<tr>
<td>Community ABSSSI</td>
<td>~735k cases</td>
<td>$2,100 (3) x ~5% = $1.5B opportunity</td>
</tr>
<tr>
<td><strong>CABP Opportunity:</strong> Fluoroquinolone failure, resistance suspected</td>
<td>Primary market research (est 18% of hospitalized CABP patients &amp; 16.5% of community CABP patients are “high-risk” and suspected/confirmed to have a resistant pathogen)</td>
<td>$1.1B opportunity</td>
</tr>
<tr>
<td>Community CABP</td>
<td>~510k cases</td>
<td>$2,100 (3) x ~6% = $1.1B opportunity</td>
</tr>
</tbody>
</table>

---

1. 20% est failures (based on hospital patterns) of first line MRSA treatment
2. Primary market research (est 18% of hospitalized CABP patients & 16.5% of community CABP patients are “high-risk” and suspected/confirmed to have a resistant pathogen)
3. Cost per course based on health outcome analysis, 7 day course of therapy and cost of branded Zyvox therapy as an analogue

Paratek estimates based on 2015 AMR data current treatment failure rates and a Zyvox 2015 pricing analogue.
NUZYRA®: U.S. Launch Underway

NUZYRA U.S. Revenues (Net)

- Launched in the U.S. in February 2019
- NUZYRA generated $3.1 million in net sales in the U.S. in the third quarter compared to $1.7 million seen in the second quarter, an increase of 82%
  - Accounting for inventory, NUZYRA gross demand nearly doubled from approximately $1.7 million in the second quarter of 2019 to approximately $3.3 million in the third quarter of 2019
- Achieved institutional access in ~60% of the 600 plus targeted hospitals as of Q3 2019
- Through Q3 2019, over 75% of commercial lives in the U.S. now have access to NUZYRA
- In Q3 2019, expanded the sales force size to ~50 representatives; will continue to judiciously add representatives throughout the balance of the year toward target of ~60
Significant Unmet Need in CABP

Important Demography:
- Together with influenza, CABP is currently the eighth leading cause of death in the U.S.\(^2\)
  - All cause 30-day mortality in hospitalized patients exceeds 10\%\(^3\)\(^-\)\(^5\)
- Hospitalization Rates in CABP are increased in older populations and in populations with certain co-morbid conditions, including COPD, CHF, and diabetes\(^6\)

CABP Pathogens\(^1\):
- S. pneumoniae
- S. aureus
- Legionella pneumophila
- H. influenzae
- Enterobacteriaceae
- Mycoplasma pneumonia
- Other

Opportunities Beyond Current CABP Treatment Options:
NUZYRA Offers a First-Line Therapy To Replace Current Treatments with Safety Concerns

IDSA/ATS CABP Guideline:¹

NUZYRA as First-Line Therapy:
Monotherapy, IV + Oral, when β-lactam/Macrolide or Quinolones are not options

Significant Unmet Need in Skin Infections

Important Demography:

- Incidence of skin infections requiring hospitalization has substantially increased since the 2000’s¹,³

- ~ 870,000 admissions, 6.3M office visits, and 3.4M emergency department visits annually⁴

- Underlying co-morbidities including diabetes and vascular disease can complicate management and antibiotic selection⁵

Common Skin Pathogens²

- MRSA
- MSSA
- Beta-hemolytic Streptococci
- Other Streptococci
- Other Gram positive
- Anaerobe
- Gram negative

Opportunities Beyond Today’s Skin Treatment Options:
NUZYRA Offer a First Line Therapy to Replace Current Treatments with Safety Concerns

IDSA SSTI Guideline:¹

**Inpatient Rx**

| Vancomycin +/- Pip/Tazo | OR | Zyvox +/- Pip/Tazo |

NUZYRA as First-Line Therapy:
Monotherapy, IV + Oral, when Vancomycin/Zyvox +/- Pip/Tazo are not options

SSTI: Skin and Soft Tissue Infection, pip/tazo: piperacillin/tazobactam
Success Begins in the Hospital with Specialists

Institutional Access [“Go-Home” Strategy] and Demand Generation

Influencers:
- IDs
- PharmD IDs
- Pharmacy Directors
- Microbiologists

Prescribers:
- IDs
- ER
- Hospitalists
- Pulmonologists

Formulary/Protocols
Specialty Access & Buying

Demand Generation

Adoption

Institutional Access + Demand Generation = Adoption
Launch in **February 2019** with **40 Sales Specialists**

- In Q3 2019, expanded the sales force size to ~50 representatives; will continue to judiciously add representatives throughout the balance of the year toward target of ~60

**Focusing on ‘Early Adopting’** HCPs in ‘high value’ institutions (~600), will drive institutional access

**Inside Sales Team supplements** efforts of Sales Specialists to broaden outreach

---

**Physician Segments**

- **Early Adopter**
  - Focused on broad spectrum and efficacy
  - Convenient features with IV to oral transition

- **Late Adopter**
  - Wait for Early Adopters to trial and use
  - Guideline and protocol driven
Ensure Seamless Transition from Hospital to Home
Continuity of Care Providing Access to Oral NUZYRA

Continuity of Care
• Prevent gap in care
• Sample / Bridge Program (as needed)

Reimbursement Support Services

Affordability Program

Distribution Network
– IV Formulation
  • National & Regional Distributors
– Oral Formulation
  • National & Regional Pharmacies
  • Program allows for oral formulation pick-up at retail locations or home delivery

HUB Services
– Enables effective discharge process
NUZYRA Life-Cycle Opportunity
Non-Tuberculous Mycobacterium Abscessus
NTM (M. abscessus) Opportunity
Potential $740 Million Addressable Market by 2028

NTM Opportunity: M. abscessus Opportunity with Oral Therapy

6,300\textsuperscript{(1)}
M. abscessus yearly incidence

\[ \geq 75\% \textsuperscript{(2)} \]
Fail triple generic Tx

\approx 4,760
patients

\$155,420\textsuperscript{(3)}
per course

\$740M
opportunity

- No approved therapies
- Triple generic IV/oral therapy is common
- Most Agents IV only
- Nearly 80% failure rate with existing treatments
- Long treatment duration typically 12-28 months


\textsuperscript{(2)} Am J Respir Crit Care Med Vol 175. pp 367-416, 2007 (“no antibiotic regimens based on in vitro susceptibilities has been shown to produce long-term sputum conversion for patients with M. abscessus lung disease. The goal of 12 months of negative sputum cultures while on therapy may be reasonable, but there is no medication strategy to reliably achieve this goal”)

\textsuperscript{(3)} 135 DOT in initial Tx to clear infection. Assuming success, avg 274 DOT (recommendation for 12mo of Tx after 3 negative cultures; assumes 75% compliance); $380 avg cost/day - blend of IV ($345/DOT) and Oral ($395/DOT)
Nontuberculous mycobacteria or “NTM”
Potential Opportunity with Omadacycline

**Prevalence of All NTM**

- 70,000 – 80,000 NTM cases in the U.S.
- 5-10% year-over-year increase in prevalence
- 5 year all-cause mortality 40%

**Radiographic Hallmarks**

- Paratek focused on subset of NTM patients (~10%) with *Mycobacterium abscessus*
  - Currently, no approved antibiotic therapies

**Pulmonary Pharmacokinetics of Omadacycline and Tigecycline**

NUZYRA Published Data in Anthrax
Compelling in vitro Activity and in vivo Efficacy

Potent in vitro activity

Potent in vivo efficacy

- Antimicrobial Agents and Chemotherapy; May 2017
- ASM Biodefense; February 25-27, 2013
IP Horizon & Balance Sheet
NUZYRA® IP Protection and Market Exclusivity
GAIN Act Ensures 10 Yrs.’ Market Exclusivity and Patent Term Extension protection to at least 2030

IP Protection:
- Key Composition of Matter Patent (U.S. 7,553,828) Expires June 2023
- Key Method of Use Patent (U.S. 9,265,740) Expires March 2029

Regulatory Protection:
- U.S. Data Exclusivity: Hatch Waxman 5-years
- GAIN Act Extension 5-years

Follow-On IP Protection:
- Issued Patents and Pending Applications Covering Salts, Polymorphs, Formulations, Methods of Use, Methods of Manufacture, Modes of Administration, and Dosage Regimens
## Strong Balance Sheet

*as of September 30, 2019*

<table>
<thead>
<tr>
<th>Key Metrics (unaudited)</th>
<th>9/30/19 balance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Cash, Cash Equivalents, and Marketable Securities</strong></td>
<td>$225.6 million</td>
</tr>
<tr>
<td><strong>Long-term Debt Obligation</strong></td>
<td>$260.4 million</td>
</tr>
<tr>
<td><strong>Basic Shares Outstanding</strong></td>
<td>32,901,446</td>
</tr>
<tr>
<td><strong>Total Potentially Dilutive Securities</strong>*</td>
<td>17,615,297</td>
</tr>
</tbody>
</table>

*Includes common stock issuable under the April 2018 convertible debt offering, options, restricted share units, warrants, and for our ESPP

**Cash runway projected through the first half of 2023**
First-ever BioShield award for an Antibiotics company

Paratek was the sole recipient

Valued at up to $285 million with potential for extension beyond
- $77 million in reimbursement for all existing post-approval obligations
- $54 million for anthrax development & U.S. onshoring of manufacturing
- $153 million purchase of NUZYRA for the Strategic National Stockpile

Extends cash runway through the first half of 2023
Paratek Investment Highlights

**NUZYRA®: Potential Blockbuster Antibiotic in Both Hospital and Community Settings**

### Potential Blockbuster Antibiotic with NUZYRA®
- 1st FDA approved and launched *once-daily oral & IV antibiotic* to treat both CABP and ABSSSI in nearly 20 years*
- > $5 Billion Potential Addressable U.S. Market**

### Capital Efficient Commercial Model
- Significant Value Proposition = Hospitalization Minimization
- Hospital Promotion with no other Branded Once-Daily Broad-spectrum Oral + IV Competitors

### BARDA Project BioShield
- BARDA Project BioShield contract awarded to for development of NUZYRA for pulmonary anthrax
- Valued up to $285 million

### Additional Pipeline Potential
- Life-cycle opportunities: Oral-Only CABP, Nontuberculous mycobacteria, Pulmonary Anthrax, Prostatitis, Rickettsial Disease
- Additional Biodefense opportunities beyond pulmonary anthrax

### Strong Balance Sheet
- Cash runway projected through the first half of 2023

---

(*) NUZYRA U.S. FDA-approved in October 2018
(**) Paratek estimates based on 2015 AMR data current treatment failure rates and a Zyvox 2015 pricing analogue and opportunity reflective of current U.S. label